Prediction of response in patients (pts) with advanced gastric cancer (AGC) who received paclitaxel-based chemotherapy: Expression of class III beta tubulin (bTubIII) and ABCB1 gene polymorphisms.

e14528 Background: Several studies looked for predictive biomarkers for treatment outcome of paclitaxel, but still now no reliable biomarkers are available. To predict clinical outcome in pts with AGC received paclitaxel-based chemotherapy, we evaluated expression of bTulIII and ABCB1 (multidrug resistance) gene polymorphisms. Methods: Sixty Pts with AGC were treated with paclitaxel combined with an infusional 5-fluorouracil and low-dose leucovorin. Expression of bTubIII was evaluated by immunohistochemistry (IHC) on formalin-fixed, paraffin-embedded tumors from the primary gastric cancer. Tumors were classified as bTulIII “low ( T/A and 3435C>T polymorphisms. The expression of bTubIII and gene polymorphisms were investigated for their association with tumor response and progression free survival (PFS). Results: The 11 of 60 Pts (18.3%) with hig...